Hydroxychloroquine, Oseltamivir and Azithromycin for the Treatment of COVID-19 Infection: An RCT
Status:
Recruiting
Trial end date:
2020-11-30
Target enrollment:
Participant gender:
Summary
To evaluate the effectiveness of Hydroxychloroquine Phosphate/Sulfate (200 mg orally 8hr
thrice a day for 5 days) vs oseltamivir (75 mg orally twice a day for 5 days) vs Azithromycin
(500 mg orally daily on day 1, followed by 250 mg orally twice a day on days 2-5) alone and
in combination (in all seven groups), in clearing the coronavirus nucleic acid from throat
and nasal swab and in bringing about clinical improvement on day 7 of follow-up (primary
outcomes).
Phase:
Phase 3
Details
Lead Sponsor:
Shehnoor Azhar
Collaborator:
Federal Task Force on Science & Technology notified by Government of Pakistan